Australian biotech firm CSL Limited (ASX: CSL) has been announced as a co-investor in the government’s Biomedical Translation Fund, developed to stimulate investment in medical science in Australia.
The co-investment will form part of a fund called the Medical Research Commercialisation Fund Biomedical Translation Fund (MRCF BTF), in which A$115 million ($86.5 million) of public funds will be matched by the same amount of private investment.
"It’s critical to foster a culture where innovation policies stimulate Australia’s capabilities to facilitate the next generation of breakthrough medicines"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze